Hologic Inc.
Hologic Announces Merger Agreement with Blackstone and TPG
Summary
Hologic, Inc. announced on October 21, 2025, that it has entered into a definitive Agreement and Plan of Merger with funds managed by Blackstone and TPG. Under the terms of the agreement, Blackstone and TPG will acquire all outstanding Hologic shares for $76 per share in cash plus a contingent value right (CVR) to receive up to $3 per share, totaling up to $79 per share. The transaction, which includes minority investments from ADIA and GIC, is expected to close in the first half of 2026 and is subject to stockholder approval and regulatory conditions. Hologic has also granted cash retention awards to certain executive officers in connection with the merger. The merger agreement and a related press release are filed as exhibits to this 8-K report.
Profitelligence Alerts
Get alerts for HOLX
Be first to know when Hologic Inc. files with the SEC.
Filing Categories
Advertisement
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Official SEC Documents
Advertisement